Fennec Pharmaceuticals (TSE:FRX) Hits New 52-Week Low at $8.16

Shares of Fennec Pharmaceuticals Inc. (TSE:FRX) hit a new 52-week low on Wednesday . The stock traded as low as C$8.16 and last traded at C$8.16, with a volume of 4000 shares traded. The stock had previously closed at C$8.26.

Fennec Pharmaceuticals Trading Down 1.2 %

The company has a debt-to-equity ratio of 1,040.68, a quick ratio of 10.17 and a current ratio of 6.93. The firm has a market capitalization of C$222.93 million, a price-to-earnings ratio of 163.20 and a beta of 0.46. The company has a 50 day moving average price of C$10.20 and a two-hundred day moving average price of C$12.50.

Fennec Pharmaceuticals (TSE:FRX) last posted its quarterly earnings data on Tuesday, May 14th. The biopharmaceutical company reported C$0.56 EPS for the quarter, missing the consensus estimate of C$0.67 by C($0.11). Fennec Pharmaceuticals had a net margin of 6.33% and a negative return on equity of 1,005.59%. The firm had revenue of C$34.21 million during the quarter, compared to analyst estimates of C$14.19 million. On average, research analysts forecast that Fennec Pharmaceuticals Inc. will post 1.1958225 EPS for the current year.

Insiders Place Their Bets

In other news, Senior Officer Adrian J. Haigh bought 22,222 shares of the stock in a transaction that occurred on Monday, April 15th. The stock was bought at an average cost of C$2.31 per share, for a total transaction of C$51,332.82. Insiders sold 25,454 shares of company stock valued at $230,291 in the last three months. 17.27% of the stock is currently owned by insiders.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.